Total revenue for the quarter reached a significant DKK 6.62 billion, approximately $1.03 billion USD, marking a substantial increase from DKK 5.45 billion, or about $845 million USD, recorded in the third quarter of the previous year. Even when factoring out the impact of strategic acquisitions and currency fluctuations, the company’s underlying business demonstrated remarkable organic growth of 11%, signaling deep-seated operational strengths and market acceptance of its core offerings. Demant’s diversified business model, encompassing hearing aid manufacturing, a sprawling network of hearing care clinics, and advanced diagnostic equipment, proved instrumental in this comprehensive growth trajectory.
Demant: A Pillar in Global Hearing Healthcare
Demant stands as a venerable institution within the global hearing healthcare ecosystem, with a history spanning over a century dedicated to improving the lives of individuals with hearing loss. Headquartered in Smørum, Denmark, the company operates through several well-established brands, most notably Oticon for hearing aids, Audika for hearing care services, and Interacoustics for diagnostic solutions. Its vertically integrated approach, which spans research and development, manufacturing, distribution, and direct-to-consumer services, allows Demant to control the quality and innovation across the entire patient journey. This integrated strategy is particularly crucial in a market characterized by an aging global population and increasing awareness of the profound impact of untreated hearing loss, driving consistent demand for sophisticated hearing solutions. The company’s commitment to innovation has consistently positioned it at the forefront of technological advancements, from early analog devices to today’s highly intelligent, AI-powered digital hearing aids.
Innovation Drives Hearing Aid Business Momentum
The hearing aid segment emerged as a primary engine of growth during the third quarter, recording a substantial 17% increase in sales to external customers compared to the third quarter of 2025. This segment’s exceptional performance was largely spearheaded by the successful introduction and rapid adoption of the Oticon Reveal. The Reveal, featuring what Demant describes as "Dual AI Technology," represents a significant leap in hearing aid capabilities, offering users enhanced sound processing, superior speech clarity in complex listening environments, and a more natural sound experience. This technology, building on Demant’s "BrainHearing" philosophy, aims to support the brain’s natural way of processing sound, thereby reducing listening effort and improving cognitive performance for users.
The launch of Oticon Reveal proved particularly impactful in the critical United States market, where its advanced features resonated strongly with consumers and hearing care professionals alike. This surge in demand directly contributed to an acceleration of sales and, importantly, an improvement in Demant’s estimated market share within the highly competitive U.S. commercial sector. The company also credited the sustained momentum from its Oticon Zeal product line, which continued to strengthen its overall hearing aid portfolio, offering consumers a range of high-performance options tailored to diverse needs and preferences. The synergy between the innovative Reveal and the established Zeal products provided a robust and attractive offering to the market.
Demant’s success in the hearing aid division was further buoyed by a dual benefit: an increase in the sheer number of hearing aids sold and a noticeable rise in the average selling price (ASP). This higher ASP signals a successful shift in the sales mix towards newer, more technologically advanced products like the Oticon Reveal, which typically command premium pricing. This strategic shift not only boosted revenue but also significantly improved profitability margins for the segment, demonstrating the effectiveness of Demant’s premiumization strategy and its ability to innovate at the higher end of the market.
Geographically, North America delivered impressive double-digit underlying growth in the hearing aid business, driven almost entirely by the United States. Beyond the commercial market, Demant also reported an improved market share within the U.S. Department of Veterans Affairs (VA) channel. The VA market, serving military veterans, represents a significant and stable segment, and gains here underscore Demant’s ability to meet stringent government procurement standards and serve a diverse patient population. While the U.S. commercial market thrived, the U.S. managed care market continued to face specific challenges, reflecting the complex reimbursement landscapes and evolving dynamics within that segment.
Europe also recorded strong growth, with particularly positive contributions emanating from key markets such as the United Kingdom, Germany, and France, reflecting a broad-based recovery and increased demand across the continent. Australia, too, performed strongly, indicating healthy market conditions in the Asia-Pacific region. However, the company noted a decline in hearing aid sales in China. This dip could be attributed to a confluence of factors, including intensifying local competition, broader economic slowdowns impacting consumer spending, and potential shifts in regulatory or distribution landscapes within the vast Chinese market. Demant will likely need to recalibrate its strategy for this crucial, albeit challenging, market.
Broader Market Dynamics: A Resurgent Global Landscape
Beyond Demant’s individual triumphs, the company’s third-quarter report offered valuable insights into the broader global hearing aid market, signaling a significant improvement in demand across the industry. Based on available industry data and its own meticulous estimates, Demant reported that global hearing aid unit sales increased by approximately 6% during the third quarter compared to the corresponding period in 2025. The overall market value growth was even more robust, climbing approximately 7%, a reflection of both increased sales volumes and a discernible shift towards higher-value, technologically advanced products across the industry. This suggests that consumers are increasingly willing to invest in premium solutions that offer superior performance and features.
The growth was not uniform across all regions. Europe demonstrated particularly strong momentum, with estimated unit sales increasing by an impressive 8%. This strong European performance could be attributed to factors such as robust public healthcare support for hearing aid provision in some countries, increasing public awareness campaigns, and a generally stable economic environment conducive to consumer spending on healthcare. North America recorded approximately 6% growth, notably supported by an 8% increase in the U.S. commercial hearing aid market, which highlights the vibrancy of private sector sales in the region.
However, the dynamics varied significantly across different distribution channels within the U.S. The VA market, while stable, grew more modestly at approximately 1%, reflecting its steady, managed demand. In contrast, the U.S. managed care market continued to grapple with challenges, indicating ongoing complexities related to insurance coverage, network restrictions, and competitive pressures within that specific segment. These figures collectively suggest that while overall hearing aid demand strengthened considerably during the quarter, growth was highly differentiated by region and distribution channel, necessitating nuanced market strategies from manufacturers. The industry also remains highly competitive, with Demant itself acknowledging "several new product launches from other manufacturers," indicating that its strong performance occurred amidst a wave of innovation from rivals.
Strategic Expansion in Hearing Care and Diagnostics
Demant’s comprehensive growth extended beyond hearing aid manufacturing, with its hearing care business – encompassing its expansive network of hearing care clinics – reporting a substantial revenue of DKK 3.28 billion, approximately $508 million USD. This represented an impressive 29% increase compared to the previous year, underscoring the strategic importance of this segment to the group’s overall health.
A significant portion of this increase stemmed from the strategic acquisition of KIND, a major German hearing care retailer. The integration of KIND has not only bolstered Demant’s market presence in Germany, one of Europe’s largest economies, but also reinforced its vertically integrated business model, allowing for greater control over the distribution and patient experience. KIND brings a strong brand reputation and an established network of clinics, providing Demant with immediate scale and market penetration. Excluding the effects of acquisitions and currency fluctuations, the underlying hearing care business still grew a healthy 6%, with positive contributions from Germany (post-KIND integration), Canada, and other international markets, reflecting robust organic growth in its existing clinic operations.
In a move to further optimize its operations and brand presence in Germany, Demant announced plans to unify its hearing care operations in the country under the established KIND name. This strategic consolidation aims to create a more cohesive and recognizable organization, leveraging KIND’s strong local brand equity to enhance customer trust, streamline operations, and realize synergies across its German retail footprint. This approach minimizes brand confusion and maximizes market impact in a key European market.
The company’s diagnostics business, which provides essential equipment and services to hearing healthcare professionals globally, also contributed positively to the quarter’s results. This segment recorded revenue of DKK 599 million, approximately $93 million USD, representing a 6% reported increase. Underlying growth in diagnostics stood at a solid 4%, supported by consistent sales of advanced diagnostic instruments, associated services, and consumable products vital for audiological assessments and fittings. Demant estimated that its diagnostics business grew slightly faster than the overall market during the quarter, suggesting its product portfolio and service offerings are highly competitive and well-regarded by professionals.
Sustained Confidence: Demant’s Upgraded 2026 Outlook and Future Strategy
Following the outstanding third-quarter performance, Demant reaffirmed the improved financial outlook it had announced in October, signaling strong confidence in its continued trajectory. The company now anticipates its underlying revenue to grow between 7% and 8% for the full year, a testament to its strong operational momentum and positive market conditions. Furthermore, Demant projects an operating profit before special items of DKK 4.7–5.0 billion, approximately $729–775 million USD, reflecting enhanced profitability driven by favorable product mix and operational efficiencies.
Looking ahead, Demant expects the overall global hearing aid market to grow approximately 4% to 5% in value during 2026. This outlook is delivered despite an acknowledgment of a competitive environment that includes several new product launches from other manufacturers, underscoring Demant’s belief in its sustained competitive edge and the market’s underlying strength. The company’s ability to maintain a positive outlook amidst heightened competition speaks to its robust product pipeline and strategic agility.
In a strong vote of confidence in its long-term financial health and value creation, Demant also resumed its share repurchase program. The company plans to buy back at least DKK 3 billion, approximately $465 million USD, in shares by the end of 2027. This share buyback program is a strategic move to return capital to shareholders, reduce the number of outstanding shares, and potentially boost earnings per share, signaling management’s strong belief in the company’s intrinsic value and future prospects.
Søren Nielsen, President and CEO of Demant, encapsulated the quarter’s success: “We delivered a very strong third quarter with 21% revenue growth for the Group, driven by particularly strong momentum in Hearing Aids and a significant contribution from the acquisition of German hearing care retailer KIND.” His statement highlights the dual engines of growth—organic innovation and strategic inorganic expansion—that propelled Demant’s exceptional performance.
Broader Implications for the Hearing Healthcare Ecosystem
For hearing healthcare professionals, Demant’s results underscore several critical industry trends. The continued demand for new hearing aid technology, particularly in the vibrant U.S. commercial market, emphasizes the importance of staying abreast of technological advancements and offering cutting-edge solutions to patients. Simultaneously, the significant investment in hearing care services and diagnostic equipment highlights the growing recognition of the need for integrated, high-quality care delivery. Professionals who embrace new technologies and comprehensive service models are likely to thrive in this evolving landscape.
The quarter’s performance also vividly illustrates how a combination of impactful product introductions, strategic clinic acquisitions, and dynamic regional market conditions are collectively shaping growth across the broader hearing healthcare industry. It suggests a market that is not only expanding but also becoming more sophisticated, with consumers increasingly seeking advanced, personalized solutions and integrated care pathways. For investors, Demant’s robust financial performance and optimistic outlook position it as a bellwether for the sector, reflecting healthy underlying market fundamentals and successful strategic execution. This holistic growth story positions Demant robustly for future challenges and opportunities in the ever-expanding global hearing healthcare market.
Source: Demant
